prostaglandin-d2 and Dermatitis

prostaglandin-d2 has been researched along with Dermatitis* in 3 studies

Reviews

1 review(s) available for prostaglandin-d2 and Dermatitis

ArticleYear
Discovery of anti-inflammatory role of prostaglandin D
    The Journal of veterinary medical science, 2016, Dec-01, Volume: 78, Issue:11

    Nonsteroidal anti-inflammatory drugs (NSAIDs) including aspirin are one of the most frequently used classes of drug worldwide and inhibit prostaglandin (PG) production by inhibiting cyclooxygenase activity. Although NSAIDs are broadly used against inflammatory diseases, they have side effects including alimentary canal disorders, kidney damage, infection and cardiovascular disorders. Thus, it is necessary to elucidate the pathophysiological role of each PG in various diseases to develop better therapies with fewer and milder side effects. PGD

    Topics: Acute Lung Injury; Animals; Capillary Permeability; Colitis; Dermatitis; Inflammation; Mice; Neoplasms; Neovascularization, Pathologic; Prostaglandin D2; Receptors, Immunologic; Receptors, Prostaglandin

2016

Other Studies

2 other study(ies) available for prostaglandin-d2 and Dermatitis

ArticleYear
Opposing immunomodulatory roles of prostaglandin D2 during the progression of skin inflammation.
    Journal of immunology (Baltimore, Md. : 1950), 2014, Jan-01, Volume: 192, Issue:1

    The effects of PGD2 are extremely context dependent. It can have pro- or anti-inflammatory effects in clinically important pathological conditions. A greater mechanistic insight into the determinants of PGD2 activity during inflammation is thus required. In this study, we investigated the role of PGD2 in croton oil-induced dermatitis using transgenic (TG) mice overexpressing hematopoietic PGD synthase. Administration of croton oil caused tissue swelling and vascular leakage in the mouse ear. Compared with wild-type animals, TG mice produced more PGD2 and showed decreased inflammation in the early phase, but more severe manifestations during the late phase. Data obtained from bone marrow transplantation between wild-type and TG mice indicated that PGD2 produced by tissue resident cells in the TG mice attenuated early-phase inflammation, whereas PGD2 produced from hematopoietic lineage cells exacerbated late-phase inflammation. There are two distinct PGD2 receptors: D-prostanoid receptor (DP) and chemoattractant receptor-homologous molecule expressed on Th2 cells (CRTH2). In TG mice, treatment with a DP antagonist exacerbated inflammation in the early phase, whereas treatment with a CRTH2 antagonist attenuated inflammation during the late phase. In vitro experiments showed that DP agonism enhanced vascular endothelial barrier formation, whereas CRTH2 agonism stimulated neutrophil migration. Collectively, these results show that when hematopoietic PGD synthase is overexpressed, tissue resident cell-derived PGD2 suppresses skin inflammation via DP in the early phase, but hematopoietic lineage cell-derived PGD2 stimulates CRTH2 and promotes inflammation during the late phase. DP-mediated vascular barrier enhancement or CRTH2-mediated neutrophil activation may be responsible for these effects. Thus, PGD2 represents opposite roles in inflammation, depending on the disease phase in vivo.

    Topics: Animals; Capillary Permeability; Chemotaxis, Leukocyte; Dermatitis; Disease Models, Animal; Disease Progression; Gene Expression; Immunologic Factors; Intramolecular Oxidoreductases; Leukocytes; Lipocalins; Mice; Neutrophils; Prostaglandin D2; Receptors, Immunologic; Receptors, Prostaglandin; Signal Transduction

2014
Time course changes of scratching counts, dermatitis symptoms, and levels of cutaneous prostaglandins in NC/Nga mice.
    Experimental dermatology, 2006, Volume: 15, Issue:11

    NC/Nga (NC) mice are known to develop dermatitis resembling atopic dermatitis (AD) in conventional (Conv) conditions, but not in specific pathogen-free (SPF) conditions. We reported that the ability of skin prostaglandin D(2) (PGD(2)) production, which might be the endogenous inhibitor of itching, was attenuated in skin-lesioned Conv-NC mice. We examined the age-related change in scratching, dermatitis symptoms, and skin PGs of SPF- and Conv-NC mice. In Conv-NC, PGD(2) increased at 7 weeks, at which scratching counts increased, but dermatitis did not develop. PGE(2), PGI(2) and PGF(2alpha) increased at 10 and 13 weeks, at which dermatitis developed. The ability to produce skin PGs was examined by measuring PGs after application of arachidonic acid or after mechanical scratching using a wire brush. In Conv-NC, PGD(2) production at 13 weeks was lower than at 7 weeks. In Conv-NC, hematopoietic PGD synthase (hPGDS) expression in the skin at 13 weeks was lower than at 7 weeks by Western blotting and immunohistochemical analysis. The increase of skin PGD(2) level in the early phase of the development of dermatitis is due to the stress of extensive scratching, but did not increase in spite of the stress of extensive scratching in the late phase, due to decreasing capacity of PGD(2) production attributable to decreasing hPGDS expression in Conv-NC mice. These results suggest that a decreased ability to produce skin PGD(2) production could enhance scratching and aggravate dermatitis in Conv-NC mice.

    Topics: Animals; Arachidonic Acid; Blotting, Western; Dermatitis; Dinoprost; Dinoprostone; Epoprostenol; Immunohistochemistry; Intramolecular Oxidoreductases; Lipocalins; Male; Mice; Mice, Mutant Strains; Prostaglandin D2; Prostaglandins; Pruritus; Severity of Illness Index; Skin; Time Factors

2006